FDA approves Wellcovorin for ultra-rare disease. The Trump admin touted it as a treatment for autism

The Food and Drug Administration (FDA) has approved Wellcovorin for the treatment of cerebral folate deficiency (CFD) in children and adults. This approval expands the drug's indications for the ultra-rare disease. Last year, the Trump administration had publicly touted Wellcovorin as a potential treatment for autism symptoms. This development marks a specific regulatory milestone for the drug in a distinct medical condition, separate from its previously discussed applications.